Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ali Murat Tatlı"'
Publikováno v:
Journal of Oncological Sciences, Vol 4, Iss 2, Pp 108-110 (2018)
Introduction: The monoclonal anti-vascular endothelial growth factor antibody bevacizumab is increasingly being used in the treatment of malignant tumors. It is the first molecular-targeted agent used in the treatment of several ovarian cancers. The
Externí odkaz:
https://doaj.org/article/b94809552cee41beb65182d9d199ae82
Autor:
Deniz Arslan, Mukremin Uysal, Ali Murat Tatlı, Seyda Gunduz, Sema Sezgin Goksu, Cumhur İbrahim Başsorgun, Hasan Senol Coskun, Hakan Bozcuk, Burhan Savaş
Publikováno v:
Case Reports in Oncological Medicine, Vol 2014 (2014)
Gastric cancer is the 5th most frequent cancer around the world and the 3rd most frequent reason of deaths due to cancer. Every year, about 1 million new cases are taking place, with varying geographical distribution. Gastric cancer is often metastat
Externí odkaz:
https://doaj.org/article/054d0336574f48e8933b3395e8874ad6
Publikováno v:
Case Reports in Oncological Medicine, Vol 2013 (2013)
Introduction. Most common metastasis sites of breast cancer are the lungs, bones, liver, and brain, whereas uterine involvement by metastatic breast disease is rare. Metastatic carcinoma of the uterus usually originates from other genital sites, most
Externí odkaz:
https://doaj.org/article/cfdd6b505b8a4ac48df2e214e4bc89d1
Autor:
Ali Murat Tatlı, Seyda Gunduz, Sema Sezgin Göksu, Deniz Arslan, Mukremin Uysal, Cumhur İbrahim Başsorgun, Hasan Şenol Coşkun
Publikováno v:
Case Reports in Oncological Medicine, Vol 2013 (2013)
Bisphosphonates are widely used in the treatment of breast cancer with bone metastases. We report a case of a female with breast cancer presented with a rash around a previous mastectomy site and a discharge lesion on her right chest wall in August 2
Externí odkaz:
https://doaj.org/article/deca4be351db4139a503ac3542f3b3c6
Autor:
Deniz Arslan, Şeyda Gündüz, Deniz Tural, Mükremin Uysal, Ali Murat Tatlı, Cumhur İbrahim Başsorgun, Gülsüm Özlem Elpek, Hasan Şenol Coşkun, Hakan Şat Bozcuk, Burhan Savaş
Publikováno v:
Case Reports in Oncological Medicine, Vol 2013 (2013)
Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal benign tumor which is generally seen in children and in young adults. It is especially located in the lungs. In histopathological examination, neoplastic fusiform cells originating from a
Externí odkaz:
https://doaj.org/article/acdc3a496a3d405ca48f72aed9cfc91e
Autor:
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Saadettin Kılıçkap, Muhammed Mustafa Atcı, Seda Kahraman, Merve Keskinkılıç, İrem Bilgetekin, Murat Ayhan, Deniz Tural, Önder Eren, Fatma Nihan Akkoç Mustafayev, Şebnem Yaman, Ali Murat Tatlı, Ertuğrul Bayram, Yasin Kutlu, İsmail Ertürk, Erkan Özcan, Ahmet Gülmez, Mustafa Korkmaz, Baran Akagündüz, Dilek Erdem, Tuğba Akın Telli, Asude Aksoy, Necdet Üskent, Yakup İriağaç, Naziyet Köse Baytemür, Dinçer Aydın, Teoman Şakalar, Hacı Arak, Fatih Selçukbiricik, Yakup Ergün, Taner Korkmaz, Naziye Ak, Çağlar Ünal, Nadiye Akdeniz, Mehmet Alpaslan Özgün, Berna Öksüzoğlu, Bülent Yalçın, İlhan Öztop, Efnan Algın, Abdullah Sakin, Adnan Aydıner, Perran Fulden Yumuk, Mehmet Ali Nahit Şendur
Publikováno v:
Future Oncology. 18:2573-2582
Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043d1a22a8f3e83e986a7039a57bac7a
https://doi.org/10.2217/fon-2022-0083
https://doi.org/10.2217/fon-2022-0083
Autor:
Mustafa Gürbüz, Yasin Kutlu, Erman Akkuş, Elif Berna Köksoy, Naziyet Köse, Bala Başak Öven, Başak Oyan Uluç, Atike Gökçen Demiray, Dilek Erdem, Bilgin Demir, Nazım Serdar Turhal, Necdet Üskent, Sinem Akbaş, Fatih Selçukbiricik, Ali İnal, Ahmet Bilici, Ömer Fatih Ölmez, Devrim Çabuk, Çağlar Ünal, Mutlu Hızal, Mehmet Ali Nahit Şendur, Mustafa Korkmaz, Nuri Karadurmuş, İsmail Ertürk, Sema Sezgin Göksu, Ali Murat Tatlı, Deniz Can Güven, Saadettin Kılıçkap, Nail Paksoy, Adnan Aydıner, Havva Yeşil Çınkır, Özlem Özkul, Akın Öztürk, Sevinç Ballı, Yasemin Kemal, Atike Pınar Erdoğan, Özlem Er, Perran Fulden Yumuk, Ahmet Demirkazık
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:3547-3555
Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a345459815bcd72a8a16fb661d35462
https://doi.org/10.1007/s00432-022-04087-x
https://doi.org/10.1007/s00432-022-04087-x
Autor:
Muzaffer Uğraklı, Mehmet Zahid Koçak, Gülhan Dinç, Tuğrul Burak Genç, Melek Çağlayan, Selin Uğraklı, Engin Hendem, Muhammed Muhiddin Er, Dilek Çağlayan, Melek Karakurt Eryılmaz, Murat Araz, Çağlayan Geredeli, Ali Murat Tatlı, Orhan Önder Eren, Mehmet Artaç
Publikováno v:
Journal of Cancer Research and Clinical Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85a788039bc355af311efa8104b1f089
https://doi.org/10.1007/s00432-023-04844-6
https://doi.org/10.1007/s00432-023-04844-6
Autor:
Dilek Çağlayan, Mehmet Zahid Koçak, Çağlayan Geredeli, Ali Murat Tatlı, Sema Sezgin Göksu, Melek Karakurt Eryılmaz, Murat Araz, Mehmet Artaç
Publikováno v:
European journal of clinical pharmacology.
Aim To evaluate the difference of progression free survival between the patients using concomitant proton pump inhibitors and non-users in the patients using CDK 4/6 inhibitors with HR + and HER2 negative mBC. Methods We included 86 patients with HR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd74c798c1377980ddcaf43d9be60a1f
https://pubmed.ncbi.nlm.nih.gov/36520173
https://pubmed.ncbi.nlm.nih.gov/36520173
Autor:
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Muhammed Mustafa Atcı, Seda Kahraman, Saadettin Kılıçkap, Merve Keskinkılıç, Murat Ayhan, Önder Eren, Fatma Nihan Akkoç Mustafayev, Şebnem Yaman, Ertuğrul Bayram, İsmail Ertürk, Erkan Özcan, Mustafa Korkmaz, Baran Akagündüz, Dilek Erdem, Tuğba Akın Telli, Asude Aksoy, Necdet Üskent, Naziyet Köse Baytemür, Ahmet Gülmez, Dinçer Aydın, Teoman Şakalar, Hacı Arak, Ali Murat Tatlı, Yakup Ergün, Naziye Ak, Çağlar Ünal, Mehmet Alpaslan Özgün, Bülent Yalçın, İlhan Öztop, Efnan Algın, Abdullah Sakin, Adnan Aydıner, Perran Fulden Yumuk, Mehmet Ali Nahit Şendur
Introduction: Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage of ALK-positive tumor cells i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb3cc0c537f79435ee24f92ba6ab7f9b
https://doi.org/10.21203/rs.3.rs-1583429/v1
https://doi.org/10.21203/rs.3.rs-1583429/v1
